IRIS
NOZZA, SILVIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.597
AS - Asia 3.538
NA - Nord America 3.322
SA - Sud America 755
Continente sconosciuto - Info sul continente non disponibili 309
AF - Africa 79
OC - Oceania 9
Totale 12.609
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.136
RU - Federazione Russa 2.675
SG - Singapore 1.207
CN - Cina 1.190
BR - Brasile 610
IT - Italia 415
HK - Hong Kong 374
RO - Romania 341
VN - Vietnam 332
SE - Svezia 274
DE - Germania 230
FR - Francia 181
GB - Regno Unito 137
BD - Bangladesh 115
FI - Finlandia 96
CA - Canada 91
IN - India 83
AR - Argentina 72
MX - Messico 61
PL - Polonia 59
ID - Indonesia 51
AT - Austria 43
NL - Olanda 36
ZA - Sudafrica 33
ES - Italia 31
IQ - Iraq 30
JP - Giappone 25
TR - Turchia 25
LT - Lituania 23
MA - Marocco 18
EC - Ecuador 17
UA - Ucraina 16
IE - Irlanda 13
VE - Venezuela 13
CO - Colombia 12
PK - Pakistan 12
MY - Malesia 11
PH - Filippine 10
AE - Emirati Arabi Uniti 9
AU - Australia 9
JM - Giamaica 9
KZ - Kazakistan 9
PY - Paraguay 9
UZ - Uzbekistan 9
BE - Belgio 8
CL - Cile 8
EG - Egitto 8
SA - Arabia Saudita 8
UY - Uruguay 7
CR - Costa Rica 5
HN - Honduras 5
JO - Giordania 5
NP - Nepal 5
PE - Perù 5
DO - Repubblica Dominicana 4
GT - Guatemala 4
IL - Israele 4
KE - Kenya 4
RS - Serbia 4
AZ - Azerbaigian 3
IR - Iran 3
NI - Nicaragua 3
SI - Slovenia 3
TN - Tunisia 3
AL - Albania 2
CH - Svizzera 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
GH - Ghana 2
KR - Corea 2
LB - Libano 2
NG - Nigeria 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
SN - Senegal 2
SY - Repubblica araba siriana 2
UG - Uganda 2
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
BY - Bielorussia 1
CG - Congo 1
CY - Cipro 1
ET - Etiopia 1
GE - Georgia 1
GR - Grecia 1
GY - Guiana 1
KG - Kirghizistan 1
KW - Kuwait 1
LK - Sri Lanka 1
LR - Liberia 1
MD - Moldavia 1
PA - Panama 1
QA - Qatar 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
VI - Stati Uniti Isole Vergini 1
Totale 12.300
Salva come PNG Salva come JPEG
Città #
Singapore 616
Moscow 529
Ashburn 388
San Jose 388
Hong Kong 367
Dallas 359
Council Bluffs 204
Shanghai 191
Beijing 180
New York 173
Hefei 152
Lauterbourg 135
Milan 113
Los Angeles 112
Ho Chi Minh City 107
Munich 98
Santa Clara 80
Lawrence 79
Princeton 79
São Paulo 68
Hanoi 64
Orem 56
Denver 49
Helsinki 47
Warsaw 45
Boardman 42
Nuremberg 42
London 39
Montreal 36
Cesano Boscone 33
Guangzhou 31
Turku 31
Chennai 30
Stockholm 29
Brooklyn 28
Atlanta 26
Poplar 26
Frankfurt am Main 25
Seattle 25
St Petersburg 24
Tokyo 24
Falkenstein 23
Gatchina 23
Rome 23
Amsterdam 22
Houston 21
Mexico City 21
Vienna 21
Da Nang 20
Manchester 20
Rio de Janeiro 20
Toronto 20
Johannesburg 19
Phoenix 19
Chicago 17
Shenzhen 17
Haiphong 16
Lappeenranta 15
Ankara 14
Boston 14
Brasília 14
Yekaterinburg 14
Baghdad 13
Belo Horizonte 13
Buffalo 13
Naples 13
Tianjin 13
Perm 12
Turin 12
Charlotte 11
Dublin 11
Jakarta 11
Mumbai 11
Nanjing 11
Philadelphia 11
Pune 11
Querétaro 11
Barnet 10
Biên Hòa 9
Dhaka 9
New Delhi 9
San Francisco 9
Tashkent 9
Brussels 8
Columbus 8
Hangzhou 8
Hải Dương 8
Memphis 8
Nizhniy Novgorod 8
Paris 8
Porto Alegre 8
Romagnano Sesia 8
St Louis 8
Washington 8
Cape Town 7
Goiânia 7
Guayaquil 7
Madrid 7
Orlando 7
Bogotá 6
Totale 5.924
Salva come PNG Salva come JPEG
Nome #
Monkeypox in a patient with undifferentiated connective tissue disease 253
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 252
Viral bloodstream detection in mpox patients: An observational multicentric study 236
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 212
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 197
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 184
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 153
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 136
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy 136
Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates between 2012 and 2023: Results from an Open Italian Cohort 135
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 135
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 133
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 130
Activating Killer Immunoglobulin Receptors and HLA-C: A successful combination providing HIV-1 control 126
Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier 125
HIV viral load monitoring during monkeypox virus infection among people with HIV 123
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 123
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 119
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 117
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 115
Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination 112
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 110
Viral Hepatitis and Human Papillomavirus Vaccination during HIV Pre-Exposure Prophylaxis: Factors Associated with Missed Vaccination 109
Monkeypox infection among men who have sex with men: PCR testing on seminal fluids 108
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy 107
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 107
Beyond stigma: Monkeypox infection in a 27-year-old woman 106
Evaluation of analytical performance of the STANDARDTM M10 MPX/OPX assay for the simultaneous DNA detection and clade attribution of Monkeypox virus 106
Beneficial effects of cART initiated during primary and chronic HIV-1 infection on immunoglobulin-expression of memory B-cell subsets 106
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 105
Monkeypox infection in a hemopoietic stem cell and heart transplant recipient 105
Tick-borne encephalitis seroprevalence in northern Italy: a cross-sectional study on a randomly selected population 104
Enhanced immunological recovery with early start of antiretroviral therapy during acute or early HIV infection–results of Italian network of acute HIV infection (Inaction) retrospective study 104
Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance 103
Rectal Lymphogranuloma venereum among Men who Have Sex with Men: 7 versus 21 Days Doxycycline Effectiveness 102
Increasing incidence and prevalence of metabolic syndrome in people living with HIV during the COVID-19 pandemic 101
Persistent ocular mpox infection in an immunocompetent individual 101
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 101
Isolated monkeypox proctitis among men who have sex with men 100
Brief Report: New HIV Diagnoses in PrEP-Experienced and PrEP-Naive Persons in the ICONA Cohort 99
A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study 99
HIV-DNA undetectability during chronic HIV infection: Frequency and predictive factors 99
The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation Cohort 99
Anti-Tat immunity defines CD4 + T-cell dynamics in people living with HIV on long-term cART 98
Prior Neisseria meningitidis (Nm) proctitis does not prevent Neisseria gonorrhoeae (Ng) proctitis among men who have sex with men (MSM) 96
Switching from a Non-Protease inhibitor-Based Regimen To the Fixed Dose Combination of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Clinical Practice 96
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort 96
A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses 96
Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona) 94
Sexually Transmitted Enteric Infections in Men Who Have Sex With Men Living With HIV Over 8 Years of Follow-up 93
HIV-NAAT use for early detection of HIV infection among high-risk men who have sex with men in Italy 92
Mpox neutralising antibodies at 6 months from mpox infection or MVA-BN vaccination: a comparative analysis 92
B-cell subset alterations and correlated factors in HIV-1 infection 90
Doravirine associated with greater LDL cholesterol reduction in people with HIV switching antiretroviral regimens 89
Antibiotic resistance among sexually transmitted infections: perspectives from clinical practice 89
Monkeypox and pan-resistant Campylobacter spp infection in Entamoeba histolytica and Chlamydia trachomatis re-infection in a man who have sex with men 88
Drop in CD4+ Counts Below 200 Cells/μL After Reaching (or Starting From) Values Higher than 350 Cells/μL in HIV-Infected Patients With Virological Suppression 88
Viral hepatitis and human papillomavirus vaccination during pre-exposure prophylaxis: factors associated with missed vaccination 86
Role of multi-site sampling in the diagnosis of human Monkeypox 85
Early Diagnosis and Linkage to Care: an Experience over 14 years of Point of Care Rapid HIV Testing 85
Late positivization of oropharyngeal, plasma, anal, semen, and urine specimens which tested negative at the time of mpox diagnosis 84
Two individuals with potential monkeypox virus reinfection 84
VIRO-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression 84
Evaluation of HIV transmission clusters among natives and foreigners living in Italy 84
Proctitis and prostatitis by Neisseria meningitidis among MSM: A case series 83
Real-life use of cidofovir for the treatment of severe monkeypox cases 79
An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. 77
Monkeypox Virus Infection in Humans across 16 Countries - April-June 2022 76
Vaccines against Emerging Sexually Transmitted Infections: Current Preventive Tools and Future Perspectives 76
Estimated glomerular filtration rate trajectories in HIV-infected subjects treated with different ritonavir-boosted protease inhibitors and tenofovir disoproxil fumarate or abacavir 76
Mpox in people with past infection or a complete vaccination course: a global case series 75
Four-year outcome of a PI and NRTI-sparing salvage regimen: maraviroc, raltegravir, etravirine 75
Pharmacokinetics of the raltegravir/maraviroc/etravirine combination 74
Monotherapy with atazanavir as a simplification strategy: results from an observational study. 74
Ageing with HIV: a multidisciplinary review 73
Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption 73
Prevalence and Risk Factors of Anal HPV Infection in MSM Living With HIV: Identifying the Target Groups to Prioritize for Immunization 72
Mpox Virus: Control of In-Hospital Occupational Transmission Experience from a Tertiary Level Hospital in Milan, Italy 71
Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen 71
Differential dynamics of Epstein-Barr virus in individuals infected with human immunodeficiency virus-1 receiving intermittent interleukin-2 and antiretroviral therapy 70
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA Study Group 70
Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients 70
Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen 70
Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex 69
Dynamics of adaptive and innate immunity inpatients treated during primary human immunodeficiency virus infection: Results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial 69
Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV 69
Maraviroc 150mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study 69
Multidrug-resistant Mycoplasma genitalium urethritis: successful eradication with sequential therapy 68
Unified European support framework to sustain the HIV cascade of care for people living with HIV including in displaced populations of war-struck Ukraine 66
Immune recovery and T cell subset analysis during effective treatment with maraviroc 63
Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males 63
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection 62
The Less Drugs Regimens (LDRs) therapy approach in HIV-1: an Italian expert panel perspective for the long-term management of HIV-1 infection. 61
Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART 61
Rapid improvement of severe Mpox lesions with oral tecovirimat 60
Resistance to amprenavir before and after treatment with lopinavir/ritonavir in highly protease inhibitor-experienced HIV patients 60
Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy 60
Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up 60
Exercise ECG for coronary artery disease screening in people living with HIV: The cordis STUDY 60
HIV-1-mediated insertional activation of STAT5B and BACH2 trigger viral reservoir in T regulatory cells 59
Totale 9.906
Salva come PNG Salva come JPEG
Categoria #
all - tutte 65.236
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 65.236
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202273 0 0 0 20 7 9 3 6 4 11 3 10
2022/2023469 178 99 20 2 1 42 48 56 9 5 4 5
2023/2024559 9 19 99 48 64 125 21 58 1 15 30 70
2024/20252.693 196 35 75 78 123 224 712 316 267 201 166 300
2025/20268.167 606 530 474 1.060 649 276 646 652 2.224 523 294 233
2026/2027574 243 331 0 0 0 0 0 0 0 0 0 0
Totale 12.609